Enzalutamide-resistant LNCaP ARF877L Mutation KI model
We have established an enzalutamide-resistant (LNCaP AR-F877L mutation) KI prostate cancer model to support the development of next-generation therapeutics. An LNCaP AR-F877L KI cell line was shown to be resistant to enzalutamide, and in vivo animal validation studies demonstrated that enzalutamide was not efficacious to prevent tumor growth using this drug-resistant model.
Check out our comprehensive platform of drug-resistant animal models
Enzalutamide-resistant LNCAP AR F877L mutant KI model
Related Content
Many oncology drug candidates with promising preclinical activity ultimately fail because safety liabilities emerge too late in development. An integrated...
VIEW RESOURCEBispecific antibodies have emerged as an important modality in oncology, although their broader application can be limited by manufacturing complexity...
VIEW RESOURCE